Screening in cervical cancer
Reading File
Searching for comprehensive information on cervical cancer screening — guidelines, methods, and special populations.
search_medical_text
cervical cancer screening guidelines Pap smear HPV testing
Harrison's Principles of Internal Medicine, Twenty First Edition
Page 1994
search_medical_text
cervical cancer screening age intervals colposcopy management abnormal results
Cervical Cancer Screening for Individuals at Average Risk
Page 1
GradeResponse
GradeResponse
Cervical Cancer Screening
Overview
Cervical cancer screening aims to detect precancerous lesions (cervical intraepithelial neoplasia, CIN) and early invasive cancer before symptoms develop. The dramatic decline in cervical cancer mortality over decades is largely attributable to widespread Pap smear screening. HPV (human papillomavirus) is the fundamental etiologic factor for cervical cancer, and HPV-based testing has become central to modern screening strategies.
Screening Methods
| Method | Description |
|---|---|
| Cytology (Pap smear) | Samples cervical cells and examines for abnormal morphology |
| Primary HPV testing | Tests directly for high-risk HPV strains; preferred by current guidelines |
| Co-testing | HPV test + cytology together; higher sensitivity than either alone |
Current Guidelines
American Cancer Society (ACS) 2020 — Preferred Strategy
(Cervical Cancer Screening for Individuals at Average Risk, p. 1)
| Age Group | Recommended Approach | Interval |
|---|---|---|
| < 25 years | No screening | — |
| 25–65 years | Primary HPV testing (preferred) | Every 5 years |
| 25–65 years | Co-testing (HPV + cytology) if primary HPV unavailable | Every 5 years |
| 25–65 years | Cytology alone if above unavailable | Every 3 years |
| > 65 years | Discontinue if adequate prior negative screening & no CIN2+ in past 25 years | — |
Co-testing and cytology-alone are considered acceptable but transitional — to be phased out as primary HPV testing becomes universally accessible.
Harrison's Principles (21st Ed., p. 1994) — Traditional Framework
- Pap testing begins at age 21, regardless of sexual debut
- Interval: every 3 years
- From age 30 onward: HPV testing added (with or without Pap); if normal, interval extends to 5 years
Note: The ACS 2020 guideline updates the start age to 25 and makes primary HPV testing the preferred strategy from age 25. The traditional age-21 start (per older USPSTF/ACOG-aligned guidance) and the newer ACS recommendation coexist; clinicians should follow the most current local/institutional guidelines.
Key Principles
- Screening before age 21 (or 25 per ACS): More harm than benefit — HPV infections are common, transient, and unlikely to progress in young individuals; overdiagnosis leads to unnecessary colposcopy and overtreatment.
- More frequent screening adds little benefit but increases harms: unnecessary procedures and overtreatment of transient lesions (Harrison's, p. 1994).
- Vaccination status does not change screening recommendations — vaccinated individuals should continue routine screening per the same schedule.
- Post-hysterectomy (for benign indications, with no cervix remaining): screening can be discontinued.
When to Stop Screening
Discontinue at age > 65 if ALL of the following are met:
- No history of CIN2 or more severe disease in the past 25 years
- Documented adequate negative prior screening in the past 10 years
Abnormal Results — Next Steps
Positive HPV and/or abnormal cytology results should be managed per the 2019 ASCCP (American Society for Colposcopy and Cervical Pathology) risk-based management consensus guidelines, which stratify follow-up by immediate and 5-year risk of CIN3+:
- Low risk: Repeat screening at extended interval
- Intermediate risk: 1-year follow-up
- High risk: Colposcopy (with or without biopsy)
- Immediate concern for invasion: Expedited evaluation/referral
Special Populations
| Population | Guidance |
|---|---|
| Immunocompromised (HIV+, transplant) | More frequent screening; some guidelines recommend annual Pap |
| DES (diethylstilbestrol) exposure in utero | Annual screening; colposcopy at initiation |
| Post-treatment for CIN2/3 | Continued surveillance for 25 years after treatment |
| Pregnancy | Routine screening should not be deferred; colposcopy acceptable, endocervical curettage avoided |
Summary Algorithm
Age < 25 → No screening
Age 25–65 → Primary HPV test every 5 years (preferred)
OR Co-test every 5 years
OR Cytology alone every 3 years
Age > 65 → Stop if criteria met (adequate prior screening, no recent CIN2+)
Abnormal → Risk-stratify per ASCCP 2019 guidelines → Repeat / 1-yr follow-up / Colposcopy
Sources: Harrison's Principles of Internal Medicine, 21st Ed. (p. 1994); ACS Cervical Cancer Screening for Individuals at Average Risk, 2020 (p. 1).
This is a shared conversation. Sign in to Orris to start your own chat.